The total number of records retrieved from this search are 30. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_2055	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2056	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2057	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2058	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2059	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result80% cell survival after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2060	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result30% cell survival after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2061	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2062	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell survival after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2063	Virus nameVaccinia virus	Virus strainGLV-1h68	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic hsd nude mice xenograft for PLC cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityReduction in tumor volume below 2000mm compared to control after 45 days	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer cell line	Immunogenic effectIncreased expression of immunological gene such as GM-CSF, IFN-gamma, IL-6,2,12,18, IP-10, MCP-1,3,5, TNF-alpha and MIP-2	Clinical trialNA	PMID21779374
IDOV_2534	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2535	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result90% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2536	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result30% cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2545	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result100% cells viable after day 1	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2546	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result80% cells viable after day 2	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2547	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result40% cells viable after day 3	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2548	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result10% cells viable after day 4	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2591	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell linePLC	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 MOI	In-vitro result10% cells are viable after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2597	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell linePLC	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration0.1 MOI	In-vitro result100% cells viavility	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2598	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell linePLC	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration1 MOI	In-vitro resultSome cells are viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2599	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell linePLC	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2600	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell linePLC	Concentration of cell line5.0E+4 cells per well	In-vitro toxicityNA	AssayCrystal violet staining	In-vitro virus concentration100 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2731	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2732	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result90% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2733	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result60% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2734	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result50% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2735	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with miR-34-a	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result90% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2736	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with miR-34-a	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2737	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with miR-34-a	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2738	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with miR-34-a	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell linePLC5	Concentration of cell line1.0E+4 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration5 MOI	In-vitro result30% cell viability after 96 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_4312	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSICB	Origin of cell lineHuman hepatoma	Cell linePLC	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration10 pfu	In-vitro result80.5 % cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedActivation of cAMP signalling leads to induced expression of antiviral factors, severe ER stress and cell apoptosis	Immunogenic effectNA	Clinical trialNA	PMID26373347